Eli Lilly and Hims & Hers Health have announced an agreement to expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the platform.
Patients can complete a consultation, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home through the Hims & Hers platform. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.
Lilly said the agreement reflects growing patient interest in seeking care, including prescription medicines, through telehealth providers, particularly as a broader range of FDA-approved GLP-1 treatments, including the daily oral medicine Foundayo, has become available.
Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, said millions of people turn to Hims & Hers for their care, and that the agreement gives those patients a more direct way to get FDA-approved Lilly medicine if prescribed. Hims & Hers CEO Andrew Dudum said the companies are working together to reach more people with obesity with access to FDA-approved Lilly medicine.
Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s and has committed not to do so in the future. The companies also committed to protecting independent clinical decision-making, so providers on the platform continue to prescribe the treatment they determine is right for each patient.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!